Denmark· DK-28106750422
IMJUDO
A tremelimumab product containing tremelimumab, registered in Denmark by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Tremelimumab is registered in 16 of 19 countries.
Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Tremelimumab · ATC L01FX20
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tremelimumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tremelimumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$779.98
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Tremelimumab
- Manufacturer
- AstraZeneca AB
- Country
- Denmark (DK)
- ATC code
- L01FX20
- ATC class
- Tremelimumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106750422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01FX20
Tremelimumab, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8c5314f-b1d2-4e31-b2d7-30f370ee6f0f GET /v1/drugs/a8c5314f-b1d2-4e31-b2d7-30f370ee6f0f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "20 mg/ml",
"auth_role": "RAP",
"dk_drugid": "28106750422",
"substance": "Tremelimumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44977"
}See everything about tremelimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.